$1.56
4.29% today
Nasdaq, Apr 01, 07:17 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$1.63
-0.35 17.68% 1M
-4.15 71.80% 6M
-0.20 10.93% YTD
-11.49 87.58% 1Y
-41.45 96.22% 3Y
-87.65 98.17% 5Y
-96.29 98.34% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.10 5.78%
ISIN
US45773H2013
Symbol
INO
Sector

Key metrics

Market capitalization $59.77m
Enterprise Value $-22.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.21
EV/Sales (TTM) EV/Sales -102.14
P/S ratio (TTM) P/S ratio 271.68
P/B ratio (TTM) P/B ratio 0.86
Revenue growth (TTM) Revenue growth -73.83%
Revenue (TTM) Revenue $220.00k
EBIT (operating result TTM) EBIT $-112.40m
Free Cash Flow (TTM) Free Cash Flow $-104.56m
Cash position $94.11m
EPS (TTM) EPS $-3.98
P/E forward negative
P/S forward 23.30
EV/Sales forward negative
Short interest 14.67%
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.22 0.22
73% 73%
100%
- Direct Costs 3.13 3.13
11% 11%
1,423%
-2.91 -2.91
9% 9%
-1,323%
- Selling and Administrative Expenses 31 31
24% 24%
13,968%
- Research and Development Expense 76 76
13% 13%
34,373%
-109 -109
16% 16%
-49,668%
- Depreciation and Amortization 3.13 3.13
11% 11%
1,423%
EBIT (Operating Income) EBIT -112 -112
16% 16%
-51,090%
Net Profit -107 -107
21% 21%
-48,750%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
14 days ago
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwrigh...
Neutral
PRNewsWire
14 days ago
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to req...
Neutral
PRNewsWire
19 days ago
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, tem...
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 134
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today